erlotinib hydrochloride
PolandDrugs containing this active substance
-
The medicinal product is intended for adult patients with advanced non-small cell lung cancer (as first-line treatment or when the disease has not responded to chemotherapy, provided specific EGFR mutations are present) and for patients with metastatic pancreatic cancer (used in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib hydrochloride 27.32 mg ATC: L01EB02
Manufacturer: Krka, d.d., Novo mesto Krka-Farma d.o.o.
-
The medicinal product is intended for adult patients with advanced non-small cell lung cancer (as first-line treatment or when the disease has not responded to chemotherapy, provided that specific EGFR mutations are present) and for patients with metastatic pancreatic cancer (used in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib hydrochloride 109.27 mg ATC: L01EB02
Manufacturer: Krka, d.d., Novo mesto Krka-Farma d.o.o.
-
The medicinal product is used in adult patients with advanced non-small cell lung cancer (as first-line treatment or when the disease has not responded to chemotherapy, provided that specific EGFR mutations are present) and in patients with metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib hydrochloride 163.9 mg ATC: L01EB02
Manufacturer: Krka, d.d., Novo mesto Krka-Farma d.o.o.